Pretreatment PET in breast cancer: Is there a role?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 12, 2012, Pages 1827-1829

  Chua, Sue ^a   Groves, Ashley M ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA 17BETA FLUOROESTRADIOL F 18; BEVACIZUMAB; ENDOGLIN; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; HYPOXIA INDUCIBLE FACTOR 1; PROTEIN TYROSINE KINASE INHIBITOR; TRACER; UNCLASSIFIED DRUG; WATER O 15;

AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; EDITORIAL; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; MAMMOGRAPHY; MEDICAL DECISION MAKING; MICROMETASTASIS; PATIENT MONITORING; PERSONALIZED MEDICINE; PHENOTYPIC VARIATION; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR VASCULARIZATION; WHOLE BODY CT; WHOLE BODY PET;

BREAST NEOPLASMS, MALE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84869083915     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2216-7     Document Type: Editorial

References (24)

1. Syed R, Bomanji J, Nagabushan N, Hughes S, Kayani I, Groves AM, et al. Impact of combined FDG PET on the management of head and neck tumour. Br J Cancer. 2005;92:1046-50. (Pubitemid 40546667)
2. Goh V, Engeldow A, Rodriguez-Justo M, Shastry M, Blackman G, Endozo R, et al. Assessment of primary colorectal cancer by integrated 18F-FDG PET/perfusion CT: decoupling of flow and metabolism occurs in early not late stage cancer. J Nucl Med. 2012;53:687-92.
3. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480-508. (Pubitemid 351355215)
4. Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics. 2007;27:S215-29.
5. Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol. 2008;26:4746-51.
6. Bernsdorf M, Berthelsen AK, Wielenga VT, Kroman N, Teilum D, Binderup T, et al. Preoperative PET/CT in early-stage breast cancer. Ann Oncol. 2012;23:2277-82.
7. Groves AM, Shastry M, Ben-Haim S, Kayani I, Malhotra A, Davidson T, et al. Defining the role of PET-CT in staging early breast cancer. Oncologist. 2012;17:613-9
8. Vinh-Hung V, Everaert H, Lamote J, Voordeckers M, van Parijs H, Vanhoeij M, et al. Diagnostic and prognostic correlates of preoperative FDG PET for breast cancer. Eur J Nucl Med Mol Imaging. 2012;39:1618-1627.
9. Facey K, Bradbury I, Laking G, Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess. 2007;11:iii-iv. xi-267.
10. Blue Cross and Blue Shield Association. FDG positron emission tomography for evaluating breast cancer. TEC Bull (Online). 2003;20:1-7.
11. Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging. 2009;36:1543-50.
12. Aukema TS, Straver ME, Valdés Olmos RA, Vogel WV. A different role for FDG PET/CT in axillary lymph node staging in breast cancer. Eur J Nucl Med Mol Imaging. 2009;36:1896-7. Author reply 1898-99.
13. Avril N, Rosé CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 2000;18:3495-502.
14. De Cicco C, Gilardi L, Botteri E, Fracassi SL, Di Dia GA, Botta F, et al. Is [(18) F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer? Breast. 2012. doi:10.1016/j.breast.2012.05.009.
15. Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer. 2008;112:995-1000. (Pubitemid 351304582)
16. Bareschino MA, Schettino C, Colantuoni G, Rossi E, Rossi A, Maione P, et al. The role of antiangiogenetic agents in the treatment of breast cancer. Curr Med Chem. 2011;18:5022-32.
17. Hong H, Yang Y, Zhang Y, Engle JW, Barnhart TE, Nickles RJ, et al. Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging. 2011;38:1335-43.
18. Liu Z, Liu S, Wang F, Liu S, Chen X. Noninvasive imaging of tumor integrin expression using (18) F-labeled RGD dimer peptide with PEG (4) linkers. Eur J Nucl Med Mol Imaging. 2009;36:1296-307.
19. Groves AM, Shastry M, Rodriguez-Justo M, Malhotra A, Endozo R, Davidson T, et al. 18F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:46-52.
20. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, Schubert EK, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med. 2002;43:500-9. (Pubitemid 34286345)
21. Semple SIK, Gilbert FJ, Redpath TW, Staff RT, Ahearn TS, Welch AE, et al. The relationship between vascular and metabolic characteristics of primary breast tumours. Eur Radiol. 2004;14:2038-45. (Pubitemid 39481174)
22. Groves AM, Wishart GC, Shastry M, Moyle P, Iddles S, Britton P, et al. Metabolic-flow relationships in primary breast cancer: feasibility of combined PET/dynamic contrast-enhanced CT. Eur J Nucl Med Mol Imaging. 2009;36:416-21.
23. Cochet A, Generali D, Fox SB, Ferrozzi F, Hicks RJ. Positron emission tomography and neoadjuvant therapy of breast cancer. J Natl Cancer Inst Monogr. 2011;2011:111-5.
24. Hodgson NC, Gulenchyn KY. Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol. 2008;26:712-20. (Pubitemid 351264383)